Prolonged responses to chimeric antigen receptor T-cell therapy for advanced multiple myeloma may depend on the composition of the patient’s post-treatment immune microenvironment, results from a retrospective study showed.
Patients with prolonged PFS after B-cell maturation antigen (BCMA)-targeted CAR-T had a higher proportion of T cells and a lower proportion of myeloid cells in the bone marrow than those who achieved shorter PFS, researchers from Emory University and University of Pennsylvania determined.
Patients with prolonged PFS had CAR T cells and other immune cells that exhibited
